Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHS-114 + Toripalimab in Advanced or Metastatic Solid Tumors
NCT06657144Phase 1Recruiting
- Start
- Apr 2025
- Primary completion
- Jan 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of CHS-114 in solid tumor (7 cohorts). Primary endpoint: Number of Participants With Treatment-emergent Adverse Events. Started Apr 2025; status: recruiting.
02
Drugs
CHS-114
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06657144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06657144.